论文信息 - Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2 positive advanced or metastatic gastric (A/MGC), esophageal (EAC), or gastroesophageal (GEJ) adenocarcinoma: The LOGiC trial. - 字舞流文

Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2 positive advanced or metastatic gastric (A/MGC), esophageal (EAC), or gastroesophageal (GEJ) adenocarcinoma: The LOGiC trial.

LBA4001 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June, 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 2...

Joon-Oh Park | M. Buyse | Y. Bang | Jianming Xu | J. Hecht | D. Slamon | M. Press | P. Hoff | Jin Li | P. Salman | S. Qin | A. Sobrero | Y. Shparyk | S. Protsenko | H. Chung | K. Jeziorski | K. Afenjar | A. Kemner | S. Santillana | T. Kaneko | Hyunchul Chung

[1] E. Woltering,et al. Gene expression profiling (GEP) to predict the primary site of metastatic neuroendocrine tumors (NETs) presenting with an unknown primary. , 2013 .

[2] J. Tabernero,et al. Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: An international phase III study (JACOB). , 2013 .

[3] E. Nakakura,et al. Treatment of liver metastases in patients with neuroendocrine tumors: A National Comprehensive Cancer Network analysis. , 2013 .

[4] T. Hwang,et al. Open-label, phase IIIb, multicenter, expanded access study of everolimus in patients with advanced neuroendocrine tumors (NET). , 2013 .